Vor BioPharma Inc (VOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.12+1.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VOR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on progressing telitacicept through Phase 3 trials and preparing for global commercialization across multiple autoimmune diseases.
Newly stated in 2026-Q2. Management emphasized advancing telitacicept through global Phase 3 trials and commercialization plans. No revenue or operating income data is available to measure financial progress; the priority is in early clinical development with no direct financial delivery yet.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan.”
Leverage positive Phase 3 TELIGAN trial results to obtain regulatory approvals for telitacicept, including recent conditional approval in China.
Newly stated in 2026-Q2 with the announcement of NMPA conditional approval in China supported by positive Phase 3 data. No revenue reported; operating losses continue, reflecting early-stage commercial status. The regulatory milestone is a key step but financial delivery is limited so far.
“Telitacicept received NMPA conditional approval for IgAN based on positive Phase 3 TELIGAN results.”
Ensure sufficient capital runway to fund operations and key catalysts through private placement financing and disciplined capital allocation.
Newly stated in 2026-Q1 with private placement raising $75M. Guidance indicates $450M cash runway into mid-2028. Operating losses persist with net income negative $62.8M in 2026-Q2. Management is maintaining capital runway through financing, delivering on funding but operating losses continue.
“Entered into a private placement agreement to raise approximately $75 million in gross proceeds.”
Address changes in board leadership including director resignations to maintain governance stability.
Newly stated in 2026-Q2 with the announcement of a director resignation. No financial impact data available. This is a governance priority with limited measurable delivery but acknowledged by management.
“Dr. Andrew Levin resigned as a Director of Vor Biopharma Inc.”
Raise capital through private placement by issuing 5,338,078 shares at $14.05 each to secure approximately $75 million in gross proceeds.
Over the trailing year it converted 0.40x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
29 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.